Circulation. 2001;104:2266-2268
doi: 10.1161/hc4401.099447
doi: 10.1161/hc4401.099447
(Circulation. 2001;104:2266.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Soluble CD40L and Cardiovascular Risk in Women
From the Leducq Center for Cardiovascular Research, Cardiovascular Medicine and the Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Uwe Schönbeck, Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Ave, LMRC 309, Boston, MA 02115. E-mail uschoenbeck{at}rics.bwh.harvard.edu
Background— The immune-signaling dyad CD40/CD40L promotes atherogenesis, and patients with unstable angina have elevated plasma levels of soluble CD40L (sCD40L) and membrane-bound CD40L. It is unknown, however, whether elevations of circulating sCD40L precede the onset of acute cardiovascular symptoms.
Methods and Results— In a prospective, nested case-control evaluation of healthy middle-aged women, mean concentrations of sCD40L at baseline were significantly higher among 130 participants who subsequently developed myocardial infarction, stroke, or cardiovascular death (cases), compared with 130 age- and smoking-matched women who remained free of cardiovascular disease (controls) during a 4-year follow-up (2.86 ng/mL for cases versus 2.09 ng/mL for controls; P=0.02). Women with concentrations above the 95th percentile of the control distribution (>3.71 ng/mL) had a significantly increased relative risk (RR) of developing future cardiovascular events (RR, 3.3; 95% CI, 1.2 to 8.6; P=0.01) that remained after adjustment for usual cardiovascular risk factors (multivariate RR, 2.8; 95% CI, 0.9 to 8.0; P=0.05).
Conclusions— High plasma concentrations of sCD40L may be associated with increased vascular risk in apparently healthy women.
Key Words: atherosclerosis • immune system • risk factors
This article has been cited by other articles:
 |
|
 |
|
  C. Antoniades, C. Bakogiannis, D. Tousoulis, A. S. Antonopoulos, and C. Stefanadis The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Hanusch-Enserer, G. Zorn, J. Wojta, C. W. Kopp, R. Prager, W. Koenig, M. Schillinger, M. Roden, and K. Huber Non-conventional markers of atherosclerosis before and after gastric banding surgery Eur. Heart J., June 2, 2009; 30(12): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Plaikner, A. Peer, G. Falkensammer, C. Schmidauer, C. Pechlaner, A. Griesmacher, O. Pachinger, and J. Mair Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department Clin. Chem., January 1, 2009; 55(1): 175 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Choudhury, I. Chung, N. Panja, J. Patel, and G. Y. H. Lip Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention Chest, September 1, 2008; 134(3): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Natal, P. Restituto, C. Inigo, I. Colina, J. Diez, and N. Varo The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2319 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brili, D. Tousoulis, C. Antoniades, C. Vasiliadou, M. Karali, N. Papageorgiou, N. Ioakeimidis, K. Marinou, E. Stefanadi, and C. Stefanadis Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation of Aorta A Randomized Cross-Over Study. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, B. Freestone, J. Patel, and G. Y. H. Lip Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis? Chest, December 1, 2007; 132(6): 1913 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease Vascular Medicine, May 1, 2007; 12(2): 113 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Zirlik, U. Bavendiek, P. Libby, L. MacFarlane, N. Gerdes, J. Jagielska, S. Ernst, M. Aikawa, H. Nakano, E. Tsitsikov, et al. TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zirlik, C. Maier, N. Gerdes, L. MacFarlane, J. Soosairajah, U. Bavendiek, I. Ahrens, S. Ernst, N. Bassler, A. Missiou, et al. CD40 Ligand Mediates Inflammation Independently of CD40 by Interaction With Mac-1 Circulation, March 27, 2007; 115(12): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kosuge, J.-i. Suzuki, G. Haraguchi, N. Koga, Y. Maejima, M. Inobe, M. Isobe, and T. Uede Critical Role of Inducible Costimulator Signaling in the Development of Arteriosclerosis Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alessandri, P. Pignatelli, L. Loffredo, L. Lenti, M. Del Ben, R. Carnevale, A. Perrone, D. Ferro, F. Angelico, and F. Violi Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2577 - 2578. [Full Text] [PDF]
|
|
|
|
 |
|
 M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]
|
|
|
|
|
|
P. Libby and P. M. Ridker Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Geraldes, S. Gagnon, S. Hadjadj, Y. Merhi, M. G. Sirois, I. Cloutier, and J.-F. Tanguay Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: An ER{alpha}-mediated pathway Cardiovasc Res, August 1, 2006; 71(3): 566 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, Y. Nishimura, T. Shimada, S. Yoshimura, Y. Funada, M. Satouchi, and M. Yokoyama Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome Chest, March 1, 2006; 129(3): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Danese, M. Sans, F. Scaldaferri, A. Sgambato, S. Rutella, A. Cittadini, J. M. Pique, J. Panes, J. A. Katz, A. Gasbarrini, et al. TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease J. Immunol., February 15, 2006; 176(4): 2617 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santilli, G. Davi, A. Consoli, F. Cipollone, A. Mezzetti, A. Falco, T. Taraborelli, E. Devangelio, G. Ciabattoni, S. Basili, et al. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., January 17, 2006; 47(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W Clarke, N. C Ward, J. H. Wu, J. M Hodgson, I. B Puddey, and K. D Croft Supplementation with mixed tocopherols increases serum and blood cell {gamma}-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes Am. J. Clinical Nutrition, January 1, 2006; 83(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman Molecular Regulation of Platelet-Dependent Thrombosis Circulation, October 25, 2005; 112(17): 2725 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Davis and M.-H. Zou CD40 Ligand-Dependent Tyrosine Nitration of Prostacyclin Synthase In Vivo Circulation, October 4, 2005; 112(14): 2184 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos, A. Zirlik, U. Schonbeck, N. Varo, S. A. Murphy, A. Khera, D. K. McGuire, G. Stanek, H. S. Lo, R. Nuzzo, et al. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2192 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel Eur. Heart J., July 2, 2005; 26(14): 1379 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Chen, H.-W. Chang, C.-J. Wu, C.-H. Yang, W. C. Hung, K.-H. Yeh, and M. Fu Percutaneous Transluminal Mitral Valvuloplasty Reduces Circulating Soluble CD40 Ligand in Rheumatic Mitral Stenosis Chest, July 1, 2005; 128(1): 36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Ajijola, P. J. Goldschmidt-Clermont, and L. L. Satterwhite CD40 Ligand: Not Bad to the Bone (Marrow), After All Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1088 - 1090. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Halldorsdottir, J. Stoker, R. Porche-Sorbet, and C. S. Eby Soluble CD40 Ligand Measurement Inaccuracies Attributable to Specimen Type, Processing Time, and ELISA Method Clin. Chem., June 1, 2005; 51(6): 1054 - 1057. [Full Text] [PDF]
|
|
|
|
|
|
U. Bavendiek, A. Zirlik, S. LaClair, L. MacFarlane, P. Libby, and U. Schonbeck Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow-Derived Cells Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Varo, P. Libby, R. Nuzzo, J. Italiano, A. Doria, and U. Schonbeck Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 81 - 87. [Abstract] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Novo, S. Basili, R. Tantillo, A. Falco, V. Davi, G. Novo, E. Corrado, and G. Davi Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis Stroke, March 1, 2005; 36(3): 673 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui The role of inflammation in atherothrombosis: implications for clinical practice Vascular Medicine, February 1, 2005; 10(1): 45 - 53. [Abstract] [PDF]
|
|
|
|
|
|
V. Sanguigni, P. Pignatelli, L. Lenti, D. Ferro, A. Bellia, R. Carnevale, M. Tesauro, R. Sorge, R. Lauro, and F. Violi Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients Circulation, February 1, 2005; 111(4): 412 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sanguigni, D. Ferro, P. Pignatelli, M. Del Ben, T. Nadia, M. Saliola, R. Sorge, and F. Violi CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia J. Am. Coll. Cardiol., January 4, 2005; 45(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michelson Platelet Function Testing in Cardiovascular Diseases Circulation, November 9, 2004; 110(19): e489 - e493. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Chilton Pathophysiology of Coronary Heart Disease: A Brief Review J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 5S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps Human bone marrow megakaryocytes and platelets express PPAR{gamma}, and PPAR{gamma} agonists blunt platelet release of CD40 ligand and thromboxanes Blood, September 1, 2004; 104(5): 1361 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation, July 27, 2004; 110(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Furman, L. A. Krueger, M. D. Linden, M. R. Barnard, A. L. Frelinger III, and A. D. Michelson Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aukrust, J. K. Damas, and N. O. Solum Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2326 - 2328. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lim, A. D. Blann, and G. Y.H. Lip Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention Circulation, June 1, 2004; 109(21): 2524 - 2528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Willerson and P. M. Ridker Inflammation as a Cardiovascular Risk Factor Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Targher and G. Zoppini Soluble CD40L in Young Type 1 Diabetic Individuals Without Clinical Microvascular and Macrovascular Complications Diabetes Care, May 1, 2004; 27(5): 1236 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the Inflammatory Response in Cardiovascular Disease Hypertension, May 1, 2004; 43(5): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.A. Harding, J. Sarma, D.H. Josephs, N.L. Cruden, J.N. Din, P.J. Twomey, K.A.A. Fox, and D.E. Newby Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers Circulation, April 27, 2004; 109(16): 1926 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Roman, B.-A. Shanker, A. Davis, M. D. Lockshin, L. Sammaritano, R. Simantov, M. K. Crow, J. E. Schwartz, S. A. Paget, R. B. Devereux, et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus N. Engl. J. Med., December 18, 2003; 349(25): 2399 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty Circulation, December 2, 2003; 108(22): 2776 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma New Markers of Inflammation and Endothelial Cell Activation: Part I Circulation, October 21, 2003; 108(16): 1917 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. S. Prasad, P. Andre, M. He, M. Bao, J. Manganello, and D. R. Phillips Soluble CD40 ligand induces {beta}3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling PNAS, October 14, 2003; 100(21): 12367 - 12371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Naghavi, P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, et al. From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part II Circulation, October 14, 2003; 108(15): 1772 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Danese, J A Katz, S Saibeni, A Papa, A Gasbarrini, M Vecchi, and C Fiocchi Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients Gut, October 1, 2003; 52(10): 1435 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, J. A. de Lemos, P. Libby, D. A. Morrow, S. A. Murphy, R. Nuzzo, C. M. Gibson, C. P. Cannon, E. Braunwald, and U. Schonbeck Soluble CD40L: Risk Prediction After Acute Coronary Syndromes Circulation, September 2, 2003; 108(9): 1049 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bereczki, E. Nagy, A. Pal, M. T. Magyar, J. Balla, G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, et al. Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples? * Arterioscler Thromb Vasc Biol, June 12, 2003; 23(6): 1129 - 1130. [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-Pascual, M. R. Bernal, A. Fernandez-Cruz, A. Veves, P. Jarolim, J. J. Varo, et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones Circulation, June 3, 2003; 107(21): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Freedman CD40-CD40L and Platelet Function: Beyond Hemostasis Circ. Res., May 16, 2003; 92(9): 944 - 946. [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, A. Imhof, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, W. Maerz, V. Hombach, and W. Koenig Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease Circulation, April 22, 2003; 107(15): 1954 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, S. Dimmeler, C. W. Hamm, M. J. van den Brand, E. Boersma, A. M. Zeiher, M. L. Simoons, and the CAPTURE Study Investigators Soluble CD40 Ligand in Acute Coronary Syndromes N. Engl. J. Med., March 20, 2003; 348(12): 1104 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman CD40 Ligand -- Assessing Risk Instead of Damage? N. Engl. J. Med., March 20, 2003; 348(12): 1163 - 1165. [Full Text] [PDF]
|
|
|
|
|
|
L. Nannizzi-Alaimo, V. L. Alves, and D. R. Phillips Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation Circulation, March 4, 2003; 107(8): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Semb, S. van Wissen, T. Ueland, T. Smilde, T. Waehre, M. D. Tripp, S. S. Froland, J. J. P. Kastelein, L. Gullestad, T. R. Pedersen, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy J. Am. Coll. Cardiol., January 15, 2003; 41(2): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, M. A. Blake, M. Gerhard, P. M. Ridker, P. Libby, and R. T. Lee Soluble CD40 Ligand Levels Indicate Lipid Accumulation in Carotid Atheroma: An In Vivo Study With High-Resolution MRI Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): e11 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck, N. Gerdes, N. Varo, R. S. Reynolds, D. B. Horton, U. Bavendiek, L. Robbie, P. Ganz, S. Kinlay, and P. Libby Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells Circulation, December 3, 2002; 106(23): 2888 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Andre, L. Nannizzi-Alaimo, S. K. Prasad, and D. R. Phillips Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease Circulation, August 20, 2002; 106(8): 896 - 899. [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, E. Dernbach, A. Aicher, A. M. Zeiher, and S. Dimmeler CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species Circulation, August 20, 2002; 106(8): 981 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, A. Mezzetti, E. Porreca, C. Di Febbo, M. Nutini, M. Fazia, A. Falco, F. Cuccurullo, and G. Davi Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia: Effects of Statin Therapy Circulation, July 23, 2002; 106(4): 399 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
L. Nannizzi-Alaimo, M. H. Rubenstein, V. L. Alves, G. Y. Leong, D. R. Phillips, and H. K. Gold Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand Circulation, June 18, 2002; 105(24): 2849 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby CD40 Signaling and Plaque Instability Circ. Res., December 7, 2001; 89(12): 1092 - 1103. [Abstract] [Full Text] [PDF]
|
|